The Food and Drug Administration (FDA) has granted Adherium clearance for the SmartTouch for Symbicort inhaler monitoring device for use with the Symbicort (budesonide and formoterol fumarate dihydrate; AstraZeneca) inhaler.
The SmartTouch for Symbicort is a monitoring device that is installed onto the patient’s inhaler to track and improve medication adherence. The novel device documents the date and time the inhaler is used and transmits this data to an app on the patient’s mobile or tablet device. Physicians can review the history of medication use and patterns and use the data to make evidence-based decisions.
The SmartTouch for Symbicort contains three buttons that help patients control the audio visual reminders, battery monitoring, and Bluetooth low-energy (BLE) pairing functions.
Symbicort, a combination asthma medication, contains a corticosteroid and a long-acting beta-2 agonist (LABA). It is indicated as maintenance treatment of asthma in patients ≥6 years old not adequately controlled on other asthma-controller medications (eg, low-medium dose inhaled corticosteroids) or those whose disease severity clearly warrants starting treatment with two maintenance therapies. In addition, it is indicated as maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and emphysema.
Symbicort is available in 80/4.5mcg and 160/4.5mcg strengths as pressurized metered-dose inhalers.
For more information call (650) 446-8589 or visit Adherium.com.